Free Trial

Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Target

-0.26 (-3.30%)
(As of 07/19/2024 ET)

Recursion Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 4 Wall Street analysts who have issued ratings for Recursion Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 2 have given a hold rating, and 2 have given a buy rating for RXRX.

Consensus Price Target

70.83% Upside
High Forecast$17.00
Average Forecast$13.00
Low Forecast$10.00

According to the 4 analysts' twelve-month price targets for Recursion Pharmaceuticals, the average price target is $13.00. The highest price target for RXRX is $17.00, while the lowest price target for RXRX is $10.00. The average price target represents a forecasted upside of 70.83% from the current price of $7.61.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.00$14.33$12.75$11.40
Forecasted Upside70.83% Upside58.38% Upside50.27% Upside10.95% Upside
Get Recursion Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

RXRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RXRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Recursion Pharmaceuticals Stock vs. The Competition

TypeRecursion PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside70.83% Upside3,282.87% Upside10.07% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4 of 5 stars
 Lower TargetOverweight ➝ Overweight$16.00 ➝ $12.00+65.98%
6/25/2024Needham & Company LLC
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00+82.01%
1/26/2024TD Cowen
4 of 5 stars
 Initiated CoverageMarket Perform
11/13/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$11.00 ➝ $10.00+75.44%
5/22/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$8.00+24.42%
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$9.00 ➝ $8.00-8.15%
11/9/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$8.00 ➝ $9.00-12.11%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:20 AM ET.

RXRX Forecast - Frequently Asked Questions

What is Recursion Pharmaceuticals' forecast for 2024?

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Recursion Pharmaceuticals is $13.00, with a high forecast of $17.00 and a low forecast of $10.00.

Should I buy or sell Recursion Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RXRX shares.

Does Recursion Pharmaceuticals's stock price have much upside?

According to analysts, Recursion Pharmaceuticals's stock has a predicted upside of 75.12% based on their 12-month stock forecasts.

What analysts cover Recursion Pharmaceuticals?

Recursion Pharmaceuticals has been rated by research analysts at KeyCorp, and Needham & Company LLC in the past 90 days.

Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors?

Analysts like Recursion Pharmaceuticals less than other "medical" companies. The consensus rating score for Recursion Pharmaceuticals is 2.50 while the average consensus rating score for "medical" companies is 2.72. Learn more on how RXRX compares to other companies.

This page (NASDAQ:RXRX) was last updated on 7/21/2024 by Staff

From Our Partners